Assisted Reproductive Technology, Infertility
Conditions
Keywords
Population-based database, Registry, Infertile couple and offspring, Longitudinal study
Brief summary
Human Assisted Reproductive Technology (ART) has become a very effective and nearly irreplaceable clinical treatment for infertility, helping millions of women achieve fertility. However, ART may still have potential health risks to mothers and offspring. To better research and monitor the efficacy and safety of ART, the investigators established CXARDR based on the real medical data in Reproductive and Genetic Hospital of CITIC-Xiangya, which is the world's largest ART single treatment center. CXARDR covers the ART full-cycle treatment records since the hospital perfected its electronic medical record system in 2016, as well as biological samples from the CITIC-Xiangya Genetic Resource Bank. From the preoperative investigation of ART to the 1-year follow-up of ART offspring, CXARDR provides the details of the whole process of treatment and the follow-up outcomes of ART patients, making up for the gap in the data of reproductive and obstetric institutions. The huge biological samples with clinical information also provide more possibilities for in-depth basic researches in the field of reproduction and genetics. During the past five years (January 2016 to November 2020), the CXARDR has accumulated data concerning more than 223,000 ART treatment cycles from 120,000 infertile couples. The CXARDR also links more than 180,000 blood samples, 65,000 follicular fluid samples, 80,000 semen samples, and 31,000 granulosa cell samples from 75,000 couples. The data volume is substantial with over 800 variables being documented, and most variables are designed as structured fields. The whole process of data access, data extraction, data processing and data analysis was conducted through a dedicated server inside the CITIC-Xiangya Data Center. All investigators cannot access sensitive information, are required to sign data confidentiality agreement, and need to be approved by the CITIC-Xiangya Ethics Committee.
Interventions
OTHERDifferent baseline characteristics and clinical management
Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
Sponsors
Central South University
West China Hospital
Reproductive & Genetic Hospital of CITIC-Xiangya
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 66 Years
Healthy volunteers
No
Inclusion criteria
* All infertile couples undergoing ART treatment in our hospital (CITIC-Xiangya) were enrolled.
Exclusion criteria
* None.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight of offspring 1 year old | Up to 1 year after delivery | Self-measurement |
| Cleavage rate | Up to 3 days after insemination | The proportion of zygotes that cleave to become embryos on Day 2 (44 ± 1 h post-insemination) . |
| Implantation rate | Up to 30 days after transplantation | The number of gestational sacs divided by the total number of embryos transferred, irrespective of whether a pregnancy was established. |
| Clinical pregnancy | Up to 30 days after transplantation | A pregnancy diagnosed by ultrasonographic examination of at least one fetus with a discernible heartbeat. |
| Miscarriage | Up to 42 weeks after transplantation | The spontaneous loss of an intrauterine pregnancy. |
| Live birth | Up to 42 weeks after transplantation | The complete expulsion or extraction from a woman of a product of fertilization, after 20 completed weeks of gestational age. |
| Gestational age at birth | Up to 42 weeks after transplantation | The age of a fetus is calculated by the best obstetric estimate determined by assessments which may include early ultrasound. |
| Birthweight | Up to 42 weeks after transplantation | Birth weight should be collected within 24 hours of birth and assessed using a calibrated electronic scale with ten-gram resolution. |
| Height of offspring 1 year old | Up to 1 year after delivery | Self-measurement |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Embryo development rate | Up to 3 days after insemination | The proportion of cleaved embryos at the 4-cell stage on Day 2 (44 ± 1 h post-insemination) or at the 8-cell stage on Day 3 (68 ± 1 h post-insemination) per normally fertilized oocyte. |
| 1PN rate | Up to 2 days after insemination | The proportion of inseminated oocytes with one pronucleus on Day 1 (17 ± 1 h post-insemination). |
| Blastocyst development rate | Up to 7 days after insemination | The proportion of blastocysts observed at 116 ± 2 h post-insemination as a function of the number of normally fertilized oocytes. |
| Proportion of good blastocysts | Up to 7 days after insemination | The proportion of blastocysts with a grade of good or higher. |
| Ectopic pregnancy | Up to 30 days after transplantation | A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization, or histopathology. |
| Gestational diabetes | Up to 30 weeks after transplantation | By oral glucose tolerance test between 24 and 28 gestational weeks (fasting glucose ≥5.1 mmol/L, 1-h glucose ≥10.0 mmol/L, 2-h glucose ≥8.5 mmol/L; one abnormal result sufficient). |
| Gestational hypertension | Up to 42 weeks after transplantation | Maternal systolic blood pressure ≥ 140 mmHg and (or) diastolic pressure ≥ 90 mmHg. |
| Major congenital anomaly | Up to 42 weeks after transplantation | Structural, functional, and genetic anomalies, that occur during pregnancy, and identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or are life-threatening, or cause death. |
| Neonatal mortality | Up to 30 days after delivery | Death of a live born baby within 28 days of birth. |
Outcome results
None listed